Search research articles
Contact Us
Filters
Showing results (541-550 of 573) with videos related to
Page
of 58
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2017
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials
Poornima Saha, Meredith M Regan, Olivia Pagani, et al.
Journal of Cancer Survivorship : Research and Practice
|
June 10, 2022
Employment trajectories of young women with breast cancer: an ongoing prospective cohort study in Italy and Switzerland
Karin Ribi, Eleonora Pagan, Isabella Sala, et al.
The Lancet. Oncology
|
March 1, 2011
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
Luca Gianni, Urania Dafni, Richard D Gelber, et al.
Breast Cancer Research and Treatment
|
October 24, 2015
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials
Meredith M Regan, Olivia Pagani, Prudence A Francis, et al.
Lancet (London, England)
|
July 23, 2013
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
Aron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, et al.
Lancet (London, England)
|
January 20, 2012
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
José Baselga, Ian Bradbury, Holger Eidtmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2016
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
Karin Ribi, Weixiu Luo, Jürg Bernhard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 21, 2021
Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
Fabio Conforti, Laura Pala, Eleonora Pagan, et al.
The Lancet. Oncology
|
March 16, 2013
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial
Viviana Galimberti, Bernard F Cole, Stefano Zurrida, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2022
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
Olivia Pagani, Barbara A Walley, Gini F Fleming, et al.
Page
of 58
Search research articles
Search
Showing results (541-550 of 573) with videos related to
Sort By:
Page
of 58
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 28, 2017
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials
Poornima Saha, Meredith M Regan, Olivia Pagani, et al.
Journal of Cancer Survivorship : Research and Practice
|
June 10, 2022
Employment trajectories of young women with breast cancer: an ongoing prospective cohort study in Italy and Switzerland
Karin Ribi, Eleonora Pagan, Isabella Sala, et al.
The Lancet. Oncology
|
March 1, 2011
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
Luca Gianni, Urania Dafni, Richard D Gelber, et al.
Breast Cancer Research and Treatment
|
October 24, 2015
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials
Meredith M Regan, Olivia Pagani, Prudence A Francis, et al.
Lancet (London, England)
|
July 23, 2013
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
Aron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, et al.
Lancet (London, England)
|
January 20, 2012
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
José Baselga, Ian Bradbury, Holger Eidtmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2016
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
Karin Ribi, Weixiu Luo, Jürg Bernhard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 21, 2021
Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion
Fabio Conforti, Laura Pala, Eleonora Pagan, et al.
The Lancet. Oncology
|
March 16, 2013
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial
Viviana Galimberti, Bernard F Cole, Stefano Zurrida, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2022
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
Olivia Pagani, Barbara A Walley, Gini F Fleming, et al.
Page
of 58